Poseida Therapeutics Inc
NASDAQ:PSTX
Products, Other Pre-Announcement
Poseida Therapeutics Gets FDA Clearance For Trial Of Myeloma Treatment
Published: 08/30/2021 12:31 GMT
Poseida Therapeutics Inc (PSTX) - Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-bcma-allo1, an Allogeneic Car-t Candidate for Relapsed/refractory Multiple Myeloma.
Poseida Therapeutics - With P-bcma-allo1 Ind Now Cleared, Actively Focused on Opening Clinical Sites With Intention to Begin Dosing Later This Year.
Poseida Therapeutics - With P-bcma-allo1 Ind Now Cleared, Actively Focused on Opening Clinical Sites With Intention to Begin Dosing Later This Year.